deltatrials
Completed PHASE3 NCT00129805

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial

Sponsor: Tanabe Pharma Corporation

Conditions Cerebral Infarction
Interventions Aspirin MCI-9042
Updated 6 times since 2017 Last updated: Aug 18, 2008 Started: Jan 31, 2001 Primary completion: Sep 30, 2004 Completion: Sep 30, 2004

A PHASE3 clinical study on Cerebral Infarction, this trial is completed. The trial is conducted by Tanabe Pharma Corporation and has accumulated 6 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Jan 2026 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tanabe Pharma Corporation
Data source: Tanabe Pharma Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.